Gizlan Tablets / Film-coated
Irbesartan
300mg
Dar Al Dawa Development & Investment Co. Ltd.
| Pack size | 30's (10's Blister x 3) |
|---|---|
| Dispensing mode | POM |
| Source | JORDAN |
| Agent | AL MUFID PHARMACEUTICALS |
| Retail Price | 50.00 AED |
Available as:
Indications
Gizlan Tablets / Film-coated is used for:
Diabetic nephropathy, Hypertension
Adult Dose
Oral
Hypertension
Adult: 150 mg once daily, may increase to 300 mg once daily if needed. Patient w/ intravascular volume depletion: Initially, 75 mg once daily.
Elderly: >75 yr Initially, 75 mg once daily.
Diabetic nephropathy in Type 2 diabetes mellitus
Adult: Initially, 75-150 mg once daily, may increase to 300 mg once daily if needed.
Child Dose
Hypertension
<6 years: Safety and efficacy not established
6-12 years: 75 mg/day PO initially; not to exceed 150 mg/day
>12 years: 150 mg/day PO initially; may be increased to 300 mg/day PO
Renal Dose
Renal impairment:
Haemodialysis: Initially, 75 mg once daily.
Mild-to-severe renal impairment: Dosage adjustment not necessary unless patient is hypovolemic
Administration
May be taken with or without food.
Contra Indications
Hypersensitivity; pregnancy and lactation.
Precautions
Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
Lactation: Potential harm to nursing infant; discontinue drug, or do not nurse
Pregnancy-Lactation
Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D
Interactions
May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Adverse Effects
Side effects of Irbesartan :
>10%
Hyperkalemia (19%)
1-10%
Dizziness (10%), Upper respiratory tract infection (URTI) (9%), Orthostatic hypotension (5%), Fatigue (4%), Diarrhea (3%), Dyspepsia (2%)
Mechanism of Action
Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
Note
Gizlan 300mg Tablets / Film-coated manufactured by Dar Al Dawa Development & Investment Co. Ltd.. Its generic name is Irbesartan. Gizlan is availble in United Arab Emirates.
Farmaco UAE drug index information on Gizlan Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.